Lead Product(s) : SL-325
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shattuck Labs Shares Positive Data on SL-325 in IBD at ECCO 2025
Details : SL-325 is a first-in-class DR3 antagonist, currently being investigated for the treatment of inflammatory bowel diseases.
Product Name : SL-325
Product Type : Antibody
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : SL-325
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Preclinical Data Supports Ziftomenib for Gastrointestinal Tumors
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Oncology Receives FDA IND Clearance For Menin Inhibitor Ziftomenib in GIST
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRX103
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tr1X Announces FDA Clearance of IND Application for TRX103 for Refractory Crohn’s Disease
Details : TRX103, a first-in-class Type 1 Treg cell therapy candidate, which is being evaluated for the treatment of patients with treatment-refractory crohn’s disease.
Product Name : TRX103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : TRX103
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SL-325
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shattuck Labs Announces SL-325, a First-In-Class DR3 Antagonist, in TL1A/DR3 Pathway
Details : SL-325 is a first-in-class antagonist antibody to DR3, the receptor for TL1A, which is being evaluated for the treatment of inflammatory bowel disease.
Product Name : SL-325
Product Type : Antibody
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : SL-325
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRP-8802 (Oral psilocybin) in patients with Irritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with IBS.
Product Name : TRP-8802
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of short bowel syndrome.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EXE-346
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXE-346 is a live biotherapeutic product (LBP) a blend of probiotic bacteria formulated in extremely high potency. The product is currently under development to manage excessive stool frequency in patients who have undergone an ileal pouch-anal anastomos...
Product Name : EXE-346
Product Type : Probiotic
Upfront Cash : Inapplicable
January 26, 2023
Lead Product(s) : EXE-346
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM-102
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Gustave Roussy
Deal Size : Undisclosed
Deal Type : Collaboration
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
Details : The therapeutic effect of immune checkpoint inhibitors (ICIs), such as antibodies to CTLA-4 and PD-1, might be enhanced by preventing bacterial antigens, toxins, and certain metabolites in the gut from interacting with the host immune system utilizing NM...
Product Name : NM-102
Product Type : Peptide
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : NM-102
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Gustave Roussy
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ST266
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ST266 is a cell-free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels. Extensive preclinical studies have shown that ST266’s multiple components result in a variety of anti-inflammatory and neuroprotecti...
Product Name : ST266
Product Type : Protein
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : ST266
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable